Navigation Links
Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2007 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, presented data from its experimental infection study at the 2007 Pediatric Academic Societies' (PAS) Annual Meeting being held in Toronto. This study represents an important component of the company's clinical development program for ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. Results demonstrated the establishment of a safe and reliable RSV infection in the upper respiratory tract of adult volunteers and as a result of this achievement, the company expects to begin a Phase II study evaluating the safety and efficacy of ALN-RSV01 in experimentally infected adults in the second quarter of this year.

The experimental infection model was designed to evaluate viral infectivity of RSV administered intranasally in healthy adult volunteers. Top-line data are summarized as follows:

-- A total of 36 subjects were exposed to RSV in 5 cohorts;

-- Escalating viral inoculums were used from log 3 to log 5 plaque forming units (PFU), a measure of viral inoculum concentration;

-- Clinical and virologic signs of infection, e.g., viral load and viral shedding, were documented;

-- 72 percent of subjects were infected with a mean incubation period of 3.2 days, duration of infection of 7 days, and viral load (by an area under the curve analysis) of 61.9 log 10 PFU-days; and,

-- No significant adverse events were observed.

"We are pleased with the progress we have made to date with the clinical development of ALN-RSV01, an RNAi therapeutic for the treatment of RSV," said Akshay Vaishnaw, M.D., Ph.D., Vice President, Clinical Research of Alnylam. "Experimental infection models have been used to develop many anti-viral treatments including those for flu and the common cold, and we believe that such a model is a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:7/22/2014)... , July 22, 2014 Research ... "Global IVD Market 2014-2018" report to their offering. ... IVDs are widely used to diagnose, monitor, and assess ... environment. IVD tests provide outcomes for earlier and more ... hospital stay, and provide accurate results. This kind of ...
(Date:7/22/2014)... England , July 22, 2014 Elekta ... announced today that The Christie NHS Foundation Trust ( ... will join a consortium whose mission is to develop ... (MRI) guided radiation therapy system. Such a system would, ... visualization of cancer targets. "The Christie ...
(Date:7/22/2014)... Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... today that the U.S. Food and Drug Administration, or ... application.  Such clearance will permit Galmed to conduct clinical ... the United States for the treatment of ...
Breaking Medicine Technology:Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4
... , ENGLEWOOD, Colo., Dec. 7 Baxa Corporation is ... week,s ASHP Midyear Clinical Meeting (MCM). DoseEdge is a ... efficiency through the management of IV and oral dose ... practice and techniques, while providing a framework for reducing ...
... Dec. 7 Genoptix, Inc. (Nasdaq: GXDX ), a ... the Deutsche Bank 2009 MedTools Investor Conference to be held ... 2009. , Genoptix,s EVP and COO, Sam Riccitelli, ... December 9, 2009. He will provide an overview of ...
Cached Medicine Technology:Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2
(Date:7/22/2014)... 2014 (HealthDay News) -- One of the largest studies ... disorder has uncovered 83 new sites on chromosomes that ... made by an international team of researchers, now bring ... the disorder to 108. Although these schizophrenia-associated ... test to predict who will or will not develop ...
(Date:7/22/2014)... French . ... to step out for a cigarette twice as often as ... those who have the hardest time shaking off the habit ... aware of. , Those insights were among the collective findings ... by a team of researchers based in part at ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 According to ... Health care, Automobile, Aerospace & Defense, Marine and Mining) ... Middle East, and Rest of the world) - Forecast ... is expected to grow at a CAGR 8.00% to ... Europe is estimated to grow at a CAGR of ...
(Date:7/22/2014)... 2014 The Middle East Drilling fluid and ... and completion fluid market in Middle East with analysis and ... in Middle East is estimated to grow from around $560 ... CAGR of 5.7%, for the given period. , Browse through ... fluid Market report, to get an idea of the in-depth ...
(Date:7/22/2014)... Diego, California (PRWEB) July 22, 2014 ... annual Most Wired survey was conducted by ... the American Hospital Association, AT&T, CareTech Solutions, ... and McKesson. The Most Wired list recognizes ... and implementation, and evaluates hospitals in four ...
Breaking Medicine News(10 mins):Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Extra exercise helps depressed smokers kick the habit faster 2Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Global Actuators Market Estimated to Reach $59.32 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 2Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 3Health News:Healthline Systems’ Clients Honored Among Most Wired for 2014 4
... as soon as possible, researchers say , MONDAY, May ... breast lesions found in women with a high risk ... suggest. , An indeterminate breast lesion is one that ... women include those who have breast cancer, a history ...
... urged to consider risks of hormone treatment, inform patients ... widely used class of prostate cancer drugs called gonadotropin-releasing ... attack, stroke and sudden death in men, a U.S. ... on initial findings from a preliminary and ongoing analysis ...
... While timely care can reduce stress among breast cancer ... compromise other factors important to care, such as safety, effectiveness, ... the April issue of the Journal of the American ... cancer diagnosis and one in eight women will receive ...
... States will have an osteoporosis-related fracture in her lifetime (1). ... 2010 issue of the Journal of the American Academy ... women will be tested and treated for osteoporosis, which if ... fractures. "Less than 10 percent of patients who sustain ...
... ... Medical Group, a Torrance, California-based healthcare organization, today announced the acquisition of Talbert ... managed care patients in Los Angeles County and Orange County, California. , ... Torrance, CA ...
... key, study finds , MONDAY, May 3 (HealthDay News) ... their children from becoming bullies by helping them with ... study suggests. , "Improving parent-child communication and parental ... on child bullying," said study author Dr. Rashmi Shetgiri, ...
Cached Medicine News:Health News:Aggressive Action Urged When Evaluating Breast Lesions 2Health News:FDA Reviews Side Effects From Prostate Cancer Therapy 2Health News:Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment 2Health News:Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment 3Health News:Women want answers, but what questions should be asked? 2Health News:Women want answers, but what questions should be asked? 3Health News:HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces 2Health News:HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces 3Health News:Involved Parents Less Likely to Raise Bullies 2
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... kit measures the biologically active form ... is a valuable prognostic marker for cardiovascular ... plasma vitamin B6 level and Coronary Heart ... reactions of homocysteine to cystathionine and then ...
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... by irradiation. Dimensions: 78 mm W x 152 ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: